NewLimit has not yet generated revenue, but investors are valuing its age-reversal science at $3.1 billion. The longevity startup, co-founded by Coinbase CEO Brian Armstrong, raised $435 million in Series C funding led by Founders Fund, more than tripling its valuation from last year. The company is developing cellular epigenetic reprogramming therapies, a high-risk approach in a longevity market where anti-aging treatments have repeatedly struggled and the FDA does not currently recognize aging itself as a disease.
The cash injection will fund the company’s first human clinical trials scheduled for next year, an accelerated timeline triggered by a discovery that successfully reversed the biological age of old human liver cells. To navigate federal regulatory hurdles, NewLimit is targeting a specific illness first rather than broad aging. The initial trial will focus on a reprogramming medicine for alcohol-related liver disease to prove the therapy can speed up liver healing after injury, shield the organ from dietary damage, and accelerate recovery from alcohol consumption.
NewLimit joins a wave of heavily funded, billionaire-backed longevity ventures, including Sam Altman’s Retro Biosciences and Jeff Bezos’s Altos Labs. The company deployed artificial intelligence and genomics technology to build therapeutic programs across metabolic, vascular, and immune health. Newly appointed Chief Executive Jacob Kimmel stated that liver diseases act as an accelerated form of the aging that affects everyone, noting that "a younger liver helps you survive that disease or recover from it much better than an old one would."
